Los Angeles Times Examines AIDS Vaccine Research After Announcement That AIDSVAX Failed To Reduce HIV Infection Rate
Following the announcement last week that Brisbane, Calif.-based VaxGen's AIDSVAX vaccine failed to reduce the HIV infection rate among participants in Phase III human trials, "researchers and advocates are not giving up," the Los Angeles Times reports. According to the Times, 19 other AIDS vaccines that use different strategies are currently in human clinical trials and other vaccines "remain in the pipeline, keeping alive the hope that at least one will someday tame the global spread" of HIV. However, researchers warn that "large-scale progress isn't expected any time soon," the Times reports (Allen, Los Angeles Times, 3/3). The complete article is available online.This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.